The Eisai Corporation of North America has announced that elderly patients suffering from MDS (also known as myleloysplastic syndromes) could benefit from doses of Dacogen.

MDS refers to a group of fatal bone marrow diseases that restrict the production of red blood cells as the disease leads to bleeding in the bone marrow. The syndromes are very similar to cancer and the big drug discovery of 2006 in this area of affliction was that Doreen could be administered by injection and be of some benefit.

The results of this study were published in mid-summer this year. The study, was conducted by the European Organisation for the Research and Treatment of Cancer (EORTC), Dacogen was administered for three days every four weeks. It was administered to 233 people over sixty years of age who were suffering from any of the MDS conditions. In order to be part of the research study, patients had to have bone marrow blast counts between 11 and 30 percent.

The improvements in mortality were statistically significant enough that the FDA did approve the drug for injection and it will now be a treatment for conditions such as refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, chronic myelomonocytic leukemia.

It is a newer treatment so a consultation with MDS treatments is highly recommended to find out what types of doses would be best for your situation. Unfortunately this prescription drug discovery is more about handling a crisis than affecting a cure.

So who exactly is Esai? It is a research based company that develops and markets therapeutic prescription drugs in the areas of oncology, critical care, gastrointestinal disorders and neurology. It is supposed to be one of the independent laboratories.